NCT05133505已完成不适用
Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- TIM-3 and Gal-9 immunohistochemical expression
研究概览
简要总结
Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
TIM-3 and Gal-9 immunohistochemical expression
时间窗: 1 day
TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry StudyDiffuse Large B Cell LymphomaDiffuse Large B-Cell Lymphoma Cell of OriginDiffuse Large B-cell Lymphoma RecurrentNCT05169203Herlev Hospital2,969
招募中
不适用
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation SequencingHodgkin LymphomaLymphomaNCT06550427National Taiwan University Hospital200
进行中（未招募）
3 期
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT06508658Genmab379
已完成
不适用
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal LeukoencephalopathyProgressive Multifocal LeukoencephalopathyNCT04453917University Hospital, Toulouse22
进行中（未招募）
3 期
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse Large B-Cell LymphomaNCT05578976Genmab900